Kura Oncology’s (KURA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report released on Monday, Benzinga reports. The brokerage currently has a $32.00 price objective on the stock.

A number of other research firms have also recently weighed in on KURA. Stifel Nicolaus lowered their target price on shares of Kura Oncology from $28.00 to $26.00 and set a buy rating on the stock in a research note on Friday, August 9th. JMP Securities reissued a market outperform rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Tuesday, June 18th. Wedbush reissued an outperform rating and issued a $37.00 target price on shares of Kura Oncology in a research note on Friday, August 9th. StockNews.com cut shares of Kura Oncology from a hold rating to a sell rating in a research note on Monday, April 15th. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Kura Oncology in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Kura Oncology presently has a consensus rating of Moderate Buy and an average target price of $30.50.

Kura Oncology Stock Up 0.1 %

Shares of KURA opened at $19.04 on Monday. The firm has a market capitalization of $1.45 billion, a P/E ratio of -8.77 and a beta of 0.88. The company has a 50-day simple moving average of $20.60 and a 200-day simple moving average of $20.69. Kura Oncology has a 52 week low of $7.41 and a 52 week high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.67 and a current ratio of 16.67.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. Kura Oncology’s revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.53) earnings per share. On average, equities research analysts expect that Kura Oncology will post -2.56 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Teresa Brophy Bair sold 2,615 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $22.15, for a total transaction of $57,922.25. Following the sale, the insider now directly owns 68,979 shares of the company’s stock, valued at $1,527,884.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.50% of the company’s stock.

Institutional Trading of Kura Oncology

Hedge funds have recently modified their holdings of the stock. Signaturefd LLC grew its stake in shares of Kura Oncology by 40.4% during the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after purchasing an additional 1,449 shares during the last quarter. SG Americas Securities LLC acquired a new position in Kura Oncology in the first quarter valued at approximately $110,000. Saxon Interests Inc. acquired a new position in Kura Oncology in the first quarter valued at approximately $201,000. Entropy Technologies LP acquired a new position in Kura Oncology in the first quarter valued at approximately $218,000. Finally, Cape Investment Advisory Inc. acquired a new position in Kura Oncology in the fourth quarter valued at approximately $176,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.